RxDoctor Payments Data

Kristin Parmeter, NP

Family · de Witt, NYNPI 1437107067

Payments from drug & device makers

$6,256in general payments, 2019–2025

Across 319 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Medtronic$1K
  • Pfizer$561
  • Boston Scientific$411
  • Nevro Corp.$374
  • Abbott$372
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,256100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,256 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$76,605
Medicare patients
260
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate198$160,355
Nucynta ErTapentadol Hcl53$61,624
UbrelvyUbrogepant38$57,411
BelbucaBuprenorphine Hcl69$55,363
Buprenorphine155$37,717
NucyntaTapentadol Hcl32$30,250
OxycontinOxycodone Hcl54$26,387
Pregabalin457$19,394
MovantikNaloxegol Oxalate40$17,772
QuliptaAtogepant15$16,247
Hysingla ErHydrocodone Bitartrate31$13,004
Gabapentin807$11,493
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen716$11,416
Tramadol Hcl ErTramadol Hcl232$11,276
Emgality SyringeGalcanezumab-Gnlm14$9,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Belbuca, Nucynta$243$307,591352 claims
AbbVieUbrelvy, Qulipta$1,516$73,65853 claims
Redhill Biopharma Inc.Movantik$30$17,77240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in de Witt

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →